Multiple sclerosis and related disorders · 2026
Real-world outcomes of cladribine in people ≥55 years of age with multiple sclerosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Smoot Kyle, Stuchiner Tamela, Gervasi-Follmar Tiffany, Chen Chiayi
Аннотация
BACKGROUND: Treatment strategies for older adults with relapsing multiple sclerosis (RMS) require reassessment, particularly for those seeking to simplify or discontinue disease‑modifying therapy (DMT). Cladribine may represent a transition option. We aimed to describe clinical outcomes and treatment‑related adverse events in individuals ≥55 years with RMS who initiated cladribine within a western US health system.
METHODS: We conducted a retrospective chart review of patients ≥18 years with RMS who received at least one course of cladribine between March 2019, and April 2024.
RESULTS: Of 267 patients reviewed, 107 were ≥55 years old (72.9% female; median age 63.0 [58.4-67.2]). During a median follow‑up of 16.0 (7.0-28.0) months, the annualized relapse rate on cladribine was 0.00. Median Expanded Disability Status Scale (EDSS) at year 2 was 3.3 (2.5-6.5; n = 44). Three patients transitioned to another DMT, with a median time to new DMT of 35.0 (19.0-35.0) months.
CONCLUSIONS: In this older cohort, most patients were stable after switching to cladribine. While cladribine was generally well-tolerated, larger prospective studies are needed to better define its effectiveness in older adults with RMS.
METHODS: We conducted a retrospective chart review of patients ≥18 years with RMS who received at least one course of cladribine between March 2019, and April 2024.
RESULTS: Of 267 patients reviewed, 107 were ≥55 years old (72.9% female; median age 63.0 [58.4-67.2]). During a median follow‑up of 16.0 (7.0-28.0) months, the annualized relapse rate on cladribine was 0.00. Median Expanded Disability Status Scale (EDSS) at year 2 was 3.3 (2.5-6.5; n = 44). Three patients transitioned to another DMT, with a median time to new DMT of 35.0 (19.0-35.0) months.
CONCLUSIONS: In this older cohort, most patients were stable after switching to cladribine. While cladribine was generally well-tolerated, larger prospective studies are needed to better define its effectiveness in older adults with RMS.